New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes (NYSE:LLY)

RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 17, 2014 /PRNewswire/ -- Empagliflozin tablets reduced hemoglobin A1C (a measure of average blood sugar over the past two to three months), body weight and several markers of abdominal fat in adults with type 2 diabetes (T2D), according to a new retrospective analysis of clinical trial data presented on behalf of Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) at the 2014 Scientific Sessions of the American Heart Association (AHA) in Chicago. Abdominal fat, also known as visceral fat, sits on or near vital organs.



New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes (NYSE:LLY)